ClinConnect ClinConnect Logo
Search / Trial NCT03322787

Effect of Exercise Training Under HFO Device on Endurance Tolerance in Patients With COPD and CRF: a Randomized Controlled Study.

Launched by ISTITUTI CLINICI SCIENTIFICI MAUGERI SPA · Oct 23, 2017

Trial Information

Current as of May 30, 2025

Completed

Keywords

ClinConnect Summary

160 patients will be enrolled in 4 different hospitals. One of those, ICS Maugeri, will contribute with 5 different Institutes \[Brescia, Pavia, Tradate (VA),Veruno (NO) and Cassano delle Murge (BA)\]. Thus the total recruiting centers will be eight.

During the whole rehabilitation period, the patients will perform one training session/day.

The patients will use medications and oxygen therapy at rest as prescribed. The patients will perform no less than 20 training sessions within a period of one month. The rehabilitative intervention will be constantly supervised by a respiratory therapi...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • COPD and CRF diagnosis under LTOT,
  • clinical stability (pH \> 7.35 and \< 7.46, no change in respiratory drugs therapy during the last seven days)
  • Exclusion Criteria:
  • orthopedic or neurological disease,
  • cognitive impairment (Mini Mental State Examination \< 22)
  • anamnestic history of ischemic heart disease or heart failure, COPD+ fibrosis and COPD+ OSAS.

About Istituti Clinici Scientifici Maugeri Spa

Istituti Clinici Scientifici Maugeri S.p.A. is a prestigious Italian healthcare organization dedicated to advancing medical research and clinical practice. With a strong focus on patient-centered care, the institution integrates innovative clinical trials into its comprehensive services, fostering collaboration between researchers and healthcare professionals. Known for its commitment to high-quality standards and ethical practices, Istituti Clinici Scientifici Maugeri S.p.A. plays a pivotal role in the development of new therapies and treatment modalities, contributing significantly to the global medical community and enhancing patient outcomes.

Locations

Lumezzane, Brescia, Italy

Patients applied

0 patients applied

Trial Officials

Michele Vitacca, MD

Principal Investigator

ICS Maugeri Lumezzane

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials